Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Teleflex (TFX), HealthTrust Rebond On Respiratory Products

Published 12/17/2017, 09:12 PM
Updated 07/09/2023, 06:31 AM

The respiratory division of Teleflex Incorporated (NYSE:TFX) has recently entered into a new group purchasing agreement with HealthTrust Purchasing Group (“HPG”) for respiratory heaters and accessories. The agreement by the name The Respiratory Heaters & Accessories (HPG-6071) became effective on Dec 1, 2017.

The agreement covers Teleflex’s full line of Active Humidification, Non Invasive Ventilation (NIV) and High Flow Nasal Cannula Therapy (“HFNCT”) products. More than 400 member hospitals of HealthTrust can now access Teleflex’s wide range of humidification products including the Hudson RCI Neptune Heated Humidifier with ConchaSmart Technology and ISO-GardHeated Wire Circuit Technology besides the recent introduction of Comfort FloPlus High Flow Nasal Cannula.

The contract also complements Teleflex’s existing General Respiratory Agreement (HPG-184) with HealthTrust. Both these contracts — exclusive for Teleflex — provide HPG members with an opportunity to consolidate their respiratory purchases with a single supplier.

Notably, HFNCT has been growing at 20% rate year over year. This therapy has been shown to improve patient outcomes and reduce 90-day mortality rates compared with noninvasive ventilation and Standard Oxygen Therapy. Based on this data, we expect Teleflex’s deal with HealthTrust to be strategically accretive to the former and might as well boost its top line significantly in the coming period.

Taking cues from above, Teleflex has been putting in a lot of efforts on strategic expansion and top-line growth. In September, the company had made a substantial investment in the growing field of Urology. It has made a $1.1 billion acquisition of NeoTract, a privately-held developer of minimally invasive and clinically effective devices.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Apart from strengthening Teleflex’s presence in the Urology market, the company expects this buyout to accelerate the company's near-term sales growth trajectory and provide it with significant sales channel opportunity. Additionally, this should enhance Teleflex's organic growth profile in the long term.

Over the past three months, Teleflex has been trading above the broader industry. The stock has gained 5.2% compared with the broader industry’s 1.1% gain during the period.

Zacks Rank & Key Picks

Teleflex carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are PetMed Express, Inc. (PETS), Align Technology, Inc. (ALGN) and Luminex Corporation (LMNX). Notably, PetMed, Align Technology and Luminexsport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 97.5% over a year.

Align Technologyhas a long-term expected earnings growth rate of 28.9%. The stock has gained 133% in a year.

Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 5.2% over the past three months.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



PetMed Express, Inc. (PETS): Free Stock Analysis Report

Teleflex Incorporated (TFX): Free Stock Analysis Report

Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Align Technology, Inc. (ALGN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.